Ask AI
ProCE Banner Series

Comprehensive Patient-Centric Care in Multiple Myeloma: Experts Unpack Challenges, Clinical Considerations, and Strategies to Optimize Care for Patients Treated With Bispecific Antibodies

In this live webinar, experts will explore the evolving role of bispecific antibodies in multiple myeloma and how pharmacists can lead in minimizing adverse events, supporting access, and enhancing comprehensive care.

  ACPE
Who Should Attend

This activity is intended for pharmacists other healthcare professionals involved in caring for patients with multiple myeloma.

All Events

Comprehensive Patient-Centric Care in Multiple Myeloma: Experts Unpack Challenges, Clinical Considerations, and Strategies to Optimize Care for Patients Treated With Bispecific Antibodies

Upcoming Events

November

18

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This  activity aims to improve learners' knowledge, competence, and performance in improving the comprehensive care of patients with R/R MM receiving bispecific antibody therapy.

Target Audience
This activity is intended for pharmacists and other healthcare professionals involved in caring for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with multiple myeloma

  • Discuss bispecific antibody-based therapeutic strategies with patients with multiple myeloma and their caregivers, taking into consideration current indications, safety profiles, dosing protocol considerations, and patient goals and preferences

  • Establish protocols and workflows with the local care team to optimize the use of agents such as tocilizumab and dexamethasone to mitigate adverse sequelae such as CRS from bispecific antibody therapy

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-339-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191